News
Australian-based biomaterial technology company Nanollose Ltd is a technology company that uses technology to turn liquid waste into rayon fibre for clothes, with minimal environmental impact.
The goal is to work with key partners who will simply take waste (instead of trees) to produce their Nularbor fibre and seamlessly integrate them into their clothing supply chain, with no retrofitting to existing machinery or processes required.
Nanollose Ltd created the world’s first wearable garment using the company’s eco-friendly Tree-Free Rayon fibre (NullarborTM), sourced from sustainable coconut waste.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
ASX Quarterlies: Records tumble, targets achieved in good news for shareholders
Health & Biotech
Nanollose finishes milestone June quarter well positioned for growth
Experts
MoneyTalks: PEAK Asset’s Ali Ukani with 4 ASX stocks that could save the world
Health & Biotech
Nanollose to launch Lee Mathews designed garment at Copenhagen global fashion summit
Health & Biotech
Nanollose inks another collaboration deal by signing MOU with major fashion retailer
Health & Biotech
Nanollose enters Paradise with forest-friendly Nullarbor fibre collab
Health & Biotech
The lucrative global vegan leather market beckons for Nanollose after key collaboration
Health & Biotech
Nanollose finishes milestone March quarter well-positioned for next growth stage
Stockhead TV
The future of fashion: Tree-free, sustainable materials developed by Nanollose
Health & Biotech
Global fashion industry watches as Nanollose completes first pilot spin of ground-breaking, eco-friendly Nullarbor-20™ lyocell fibre
Health & Biotech
Supermodel and environmental activist, Arizona Muse, models Nanollose’s tree-free garment
Health & Biotech
Why Nanollose is on the verge of a major market opportunity with its fibre conversion technology, as global fashion brands come knocking
Health & Biotech
Check up: 78 biotech companies rocked the boat this week but only one has real news
Health & Biotech
Check Up: Imagion and Invion both target breast cancer clinical trials
News
Closing Bell: Today’s biggest small cap movers on the ASX
Health & Biotech
Medical devices tracker: All the life-saving gadgets ASX companies are working on right now
Health & Biotech